» Articles » PMID: 37510129

Hepatic Venous Pressure Gradient Predicts Further Decompensation in Cirrhosis Patients with Acute Esophageal Variceal Bleeding

Overview
Specialty Radiology
Date 2023 Jul 29
PMID 37510129
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of hepatic venous pressure gradient (HVPG) in predicting further decompensation in cirrhosis patients with acute variceal bleeding (AVB) is not known. We aimed to evaluate the role of HVPG in predicting further decompensation in cirrhosis patients with AVB Methods: In this prospective study, 145 patients with cirrhosis with esophageal or gastric AVB were included. HVPG was measured on the day of the AVB. Decompensating events occurring after 42-days of AVB were considered further decompensation.

Results: The median age of the study cohort was 44 years; 88.3% males. The predominant etiology of cirrhosis was alcohol (46.2%). Overall, 40 (27.6%) patients developed further decompensation during median follow-up of 296 days following AVB. Gastro intestinal bleeding = 27 (18.6%) and new-onset/worsening ascites = 20 (13.8%) were the most common decompensating events. According to the multivariate model, HVPG was an independent predictor of any further decompensation in esophageal AVB patients but not in gastric variceal bleeding patients. HVPG cut-off of ≥16 mmHg predicted further decompensation in the esophageal AVB. However, HVPG was not an independent predictor of mortality.

Conclusion: HVPG measured during an episode of acute variceal hemorrhage from esophageal varices predicts further decompensating events in cirrhosis patients.

Citing Articles

Case report: Management of liver cancer complicated by gastric varices rupture and bleeding: transjugular intrahepatic portosystemic shunt utilizing the mesenteric venous pathway.

Sun G, Wang J, Zhang B, Zheng N Front Med (Lausanne). 2024; 11:1388584.

PMID: 38962741 PMC: 11220234. DOI: 10.3389/fmed.2024.1388584.


Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension.

Li X, Liu S, Li J, Liu N, Li H, Ge A Int J Gen Med. 2024; 17:1493-1498.

PMID: 38655006 PMC: 11036329. DOI: 10.2147/IJGM.S453107.

References
1.
Baffy G, Bosch J . Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?. J Hepatol. 2021; 76(2):458-463. DOI: 10.1016/j.jhep.2021.09.029. View

2.
De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

3.
Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P . Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014; 60(6):1310-24. DOI: 10.1016/j.jhep.2014.01.024. View

4.
Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

5.
Villanueva C, Torres F, Sarin S, Shah H, Tripathi D, Brujats A . Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol. 2022; 77(4):1014-1025. DOI: 10.1016/j.jhep.2022.05.021. View